Physician profile
Ellery Isaac
NPI 1639699135
$14,464.63
in general payments reported to CMS, 2019-2025
23 companies · $783 in 2025
The $783 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $4,400 · 2021: $1,211 · 2022: $1,720 · 2023: $1,172 · 2024: $4,171 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135 · Consulting Fee: $1,500 · Travel and Lodging: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.97 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $1,490.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $9,102.43 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $861.96 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Bausch & Lomb Americas INC. | $512.11 | 2022-2025 | Infuse, Miebo, Xiidra |
| Allergan, INC. | $507.04 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $490.16 | 2019-2021 | |
| Coopervision INC. | $427.72 | 2023-2025 | Clariti Contact Lens, Myday Contact Lens, Ortho-K Contact Lens |
| Sun Pharmaceutical Industries INC. | $406.51 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $288.88 | 2024-2025 | Xdemvy |
| Abbvie INC. | $238.87 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $224.80 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $175.42 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $170.21 | 2021-2022 | |
| Visioneering Technologies, INC. | $168.13 | 2019-2020 | |
| Shire North American Group INC | $154.54 | 2019 | |
| Biotissue Holdings INC. | $147.75 | 2019-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $143.91 | 2021-2023 | Humphrey Hfa |
| Johnson & Johnson Surgical Vision, INC. | $142.49 | 2020-2021 | |
| Oyster Point Pharma, INC. | $130.90 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $76.21 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $40.03 | 2024 | Tearcare System |
| Lombart Brothers, INC. | $25.31 | 2022 | |
| Spark Therapeutics, INC. | $15.80 | 2021 | |
| Glaukos Corporation | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellery Isaac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.